Octapharma - Blood Disorder Treatment products (inc Haemophilia A & B)
Norfolk and Norwich University Hospitals NHS Foundation TrustcontractContracts Finder ↗Ref CF-2915000D0O000000rwimUAAcomplete
Estimated value
£72k
Awarded value
£72k
Awarded 01 Jan 2025
Suppliers
1
Lots
1
1 awarded
Published
12 Mar 2025
Deadline 31 Dec 2024
Description
Call off contract/order from the NHS National Framework Agreement for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. Offer reference number: CM/PHS/22/5661 Specifically for products: Fibryga Octaplas
Scope
- Reference
- CF-2915000D0O000000rwimUAA
- Total value
- £71,550 excluding VAT
- Commercial tool
- Standalone contract
- Contract dates
- 01 Jan 2025 to 29 Apr 2027
- CPV classifications
- 33600000
Submission & procedure
- Submission deadline
- 31 Dec 2024, 12:00 pm
Award details
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
£72k
Award date
01 Jan 2025
Contract start
01 Jan 2025
Contract end
29 Apr 2027
Awarded to
Awarded suppliers· 1 supplier
Awarded 01 Jan 2025 · Contract period 01 Jan 2025 — 29 Apr 2027
Award value
£72k
Other contracts from Norfolk and Norwich University Hospitals NHS Foundation Trust
Full notice and award history for this contracting authority is on the buyer profile.
Other contracts awarded to Octapharma Limited· 10
Cross-buyer view of this supplier's public-sector wins.
| Title | Type | Value | Published |
|---|---|---|---|
| NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin | contract | — | 20 Jan 2025 |
| Human Derived Blood Products | contract | — | 28 Aug 2024 |
| NHS Framework - Blood Disorders including Haemophilia A and B - July 2024 | contract | — | 11 Jun 2024 |
| Octapharma Ltd - Octaplas LG | contract | £53k | 14 Jun 2023 |
| Octaplex Treatment | contract | £100k | 10 May 2023 |
| Blood product required for the treatment of TTP patients | contract | £98k | 03 Aug 2022 |
| NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B | contract | — | 04 Jul 2022 |
| Human Normal Immunoglobulin and Anti-D Immunoglobulin | contract | £64.3m | 23 Jul 2021 |
| NHS Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin | contract | — | 22 Jul 2021 |
| NHS Framework Agreement for the Supply of Human Normal Immunoglobulin (Panzyga) | contract | — | 11 Jun 2021 |